Should I buy or sell Mustang Bio stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MBIO shares. View MBIO analyst ratings or view top-rated stocks .

What is Mustang Bio's stock price target for 2024?

3 analysts have issued 1-year target prices for Mustang Bio's stock. Their MBIO share price targets range from $10.00 to $25.00. On average, they predict the company's stock price to reach $17.25 in the next year. This suggests a possible upside of 4,949.8% from the stock's current price. View analysts price targets for MBIO or view top-rated stocks among Wall Street analysts .

How have MBIO shares performed in 2024?

Mustang Bio's stock was trading at $1.35 on January 1st, 2024. Since then, MBIO stock has decreased by 74.7% and is now trading at $0.3416. View the best growth stocks for 2024 here .

Are investors shorting Mustang Bio?

Mustang Bio saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 178,000 shares, a decrease of 54.2% from the March 15th total of 389,000 shares. Based on an average trading volume of 154,600 shares, the days-to-cover ratio is currently 1.2 days. Currently, 2.4% of the company's stock are sold short. View Mustang Bio's Short Interest .

When is Mustang Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our MBIO earnings forecast .

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) posted its quarterly earnings data on Monday, March, 11th. The company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($1.68) by $0.97.

When did Mustang Bio's stock split?

Mustang Bio shares reverse split before market open on Tuesday, April 4th 2023. The 1-15 reverse split was announced on Tuesday, April 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Mustang Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , CymaBay Therapeutics (CBAY) , TG Therapeutics (TGTX) , VBI Vaccines (VBIV) , Fortress Biotech (FBIO) , Viking Therapeutics (VKTX) , Selecta Biosciences (SELB) , Aytu BioPharma (AYTU) and Kadmon (KDMN) .

How do I buy shares of Mustang Bio?

Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MBIO

Mustang Bio (MBIO) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free MBIO Stock Alerts

$0.34

-0.03 (-8.07%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.34
▼
$0.40
50-Day Range: $0.34
▼
$1.39
52-Week Range: $0.33
▼
$8.17

Volume: 129,383 shs
Average Volume: 177,262 shs
Market Capitalization: $3.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.25

Get Mustang Bio alerts:

Mustang Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 4,949.8% Upside
$17.25 Price Target
Short Interest: Healthy
2.35% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.11
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.65 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Mustang Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Mustang Bio has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.35% of the float of Mustang Bio has been sold short.
Short Interest Ratio / Days to Cover
Mustang Bio has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Mustang Bio has recently decreased by 54.24%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Mustang Bio does not currently pay a dividend.
Dividend Growth
Mustang Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MBIO.

1.6

News and Social Media Coverage

News Sentiment
Mustang Bio has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Mustang Bio this week, compared to 0 articles on an average week.
Search Interest
3 people have searched for MBIO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Mustang Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mustang Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.10% of the stock of Mustang Bio is held by insiders.
Percentage Held by Institutions
Only 9.95% of the stock of Mustang Bio is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Mustang Bio is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mustang Bio is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mustang Bio has a P/B Ratio of 34.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Mustang Bio Stock (NASDAQ:MBIO)

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

MBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MBIO Stock News Headlines

April 16, 2024 | bizjournals.com

Biotech cites federal review of deal with Chinese firm in latest staff cuts

April 15, 2024 | msn.com

Mustang Bio stock tumbles 27% amid news of mass layoffs

April 20, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

April 14, 2024 | investing.com

Mustang Bio announces major workforce reduction

April 12, 2024 | marketwatch.com

Mustang Bio to Cut Global Headcount by 81%

March 28, 2024 | globenewswire.com

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

March 11, 2024 | globenewswire.com

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

March 7, 2024 | tmcnet.com

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Glioma

April 20, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 7, 2024 | markets.businessinsider.com

Why Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket

March 7, 2024 | globenewswire.com

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

February 13, 2024 | uk.investing.com

Mustang Bio Inc (MBIO)

January 11, 2024 | finance.yahoo.com

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

January 6, 2024 | morningstar.com

Mustang Bio Inc MBIO

December 27, 2023 | benzinga.com

Mustang Bio Stock (NASDAQ:MBIO) Dividends: History, Yield and Dates

December 22, 2023 | seekingalpha.com

MBIO Mustang Bio, Inc.

December 12, 2023 | msn.com

Mustang Bio files to sell 2.74M shares of common stock for holders

November 15, 2023 | markets.businessinsider.com

Mustang Bio’s Positive Financial Performance and Promising Clinical Developments Drive Buy Rating

November 15, 2023 | finanznachrichten.de

Mustang Bio, Inc.: Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

November 2, 2023 | finance.yahoo.com

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

October 30, 2023 | finance.yahoo.com

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

October 26, 2023 | marketwatch.com

Mustang Bio Shares Rise 13% After FDA Acceptance of IND Application

October 26, 2023 | finance.yahoo.com

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

August 25, 2023 | nasdaq.com

Cantor Fitzgerald Reiterates Mustang Bio (MBIO) Overweight Recommendation

August 15, 2023 | finanznachrichten.de

Mustang Bio, Inc.: Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

August 15, 2023 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Mustang Bio

August 15, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Mustang Bio (MBIO)

See More Headlines

Receive MBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MBIO
CUSIP: N/A
CIK: 1680048
Web: www.mustangbio.com
Phone: (781) 652-4500
Fax: N/A
Employees: 80
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.25
High Stock Price Target: $25.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +4,949.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,600,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -433.08%
Return on Assets: -146.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.74
Quick Ratio: 0.74

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.01 per share
Price / Book: 34.16

Miscellaneous

Outstanding Shares: 10,390,000
Free Float: 10,172,000
Market Cap: $3.55 million
Optionable: Not Optionable
Beta: 1.58

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Michael S. Weiss Esq. (Age 58)
Executive Chairman
Comp: $60k
Dr. Manuel Litchman M.D. (Age 70)
President, CEO & Director
Comp: $480.79k
Mr. James B. Murphy (Age 67)
Interim Chief Financial Officer
Mr. Peter Carney (Age 37)
Controller & Interim Chief Accounting Officer
Mr. Matthew Wein J.D.
VP & General Counsel
Ms. Debra Manning SPHR
Senior VP & Head of Human Resources
Ms. Lynn E. Bayless M.S.
VP & Head of Regulatory Affairs
Dr. Bruce Dezube M.D.
Senior VP & Head of Clinical Development
Mr. Greg Furrow M.S.
Chief Quality Officer
Mr. Richard Bodmer M.S.
Head of CMC Development

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Bought 435,764 shares on 2/13/2024
Ownership: 4.726%

View All Institutional Transactions

MBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Mustang Bio stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MBIO shares.
View MBIO analyst ratings or view top-rated stocks.
What is Mustang Bio's stock price target for 2024?: 3 analysts have issued 1-year target prices for Mustang Bio's stock. Their MBIO share price targets range from $10.00 to $25.00. On average, they predict the company's stock price to reach $17.25 in the next year. This suggests a possible upside of 4,949.8% from the stock's current price.
View analysts price targets for MBIO or view top-rated stocks among Wall Street analysts.
How have MBIO shares performed in 2024?: Mustang Bio's stock was trading at $1.35 on January 1st, 2024. Since then, MBIO stock has decreased by 74.7% and is now trading at $0.3416.
View the best growth stocks for 2024 here.
Are investors shorting Mustang Bio?: Mustang Bio saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 178,000 shares, a decrease of 54.2% from the March 15th total of 389,000 shares. Based on an average trading volume of 154,600 shares, the days-to-cover ratio is currently 1.2 days. Currently, 2.4% of the company's stock are sold short.
View Mustang Bio's Short Interest.
When is Mustang Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our MBIO earnings forecast.

How were Mustang Bio's earnings last quarter?: Mustang Bio, Inc. (NASDAQ:MBIO) posted its quarterly earnings data on Monday, March, 11th. The company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($1.68) by $0.97.
When did Mustang Bio's stock split?: Mustang Bio shares reverse split before market open on Tuesday, April 4th 2023. The 1-15 reverse split was announced on Tuesday, April 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Mustang Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Fortress Biotech (FBIO), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Aytu BioPharma (AYTU) and Kadmon (KDMN).
How do I buy shares of Mustang Bio?: Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MBIO) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial